We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Heiq Plc | HEIQ | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.23 | 2.54% | 9.28 | 16:35:12 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.82 | 8.82 | 9.10 | 9.28 | 9.05 |
| Industry Sector |
|---|
| CHEMICALS |
| Top Posts |
|---|
Posted at 05/1/2024 06:49 by piedro FWIW ...Industry Talk HeiQ’s biobased technologies unlock better sleep HeiQ Skin Care, HeiQ Allergen Tech, HeiQ Cool, and HeiQ Mint will be showcased at the Heimtextil show in Frankfurt this month. |
Posted at 09/11/2023 17:18 by hedgehog 100 LSE % Losers Top ListsEPIC Name % NEO Neo Energy Metals -99% SIV Sivota -41% HEIQ Heiq -28% HEIQ is showing as third on ADVFN's top fallers list today, but it's really second, as the NEO figure is incorrect (due to it having taken over a historic ticker today). A HEIQ fall of 5p to 13p, on volume of 925,391 shares traded. But even 13p is still quite a sizeable market cap. of £18.27M. though. After the big volume you would expect on the first day back from suspension, this is fairly comparable to its other daily volume since then. Two big trades were reported after hours, one buy and one sell, but with the buy trade being by far the bigger. Date Time Trade Prc Volume Buy/Sell Bid Ask Value 09-Nov-23 16:37:32 13.00 300,000 Sell* 13.00 13.40 39.00k O 09-Nov-23 16:37:28 13.71405 102,048 Buy* 13.00 13.40 13.99k O |
Posted at 06/11/2023 14:09 by hedgehog 100 30/10/2023 07:01 UK Regulatory (RNS & others) HeiQ PLC Interim Results LSE:HEIQ Heiq Plc"Half year results for the period ended 30 June 2023 ... Financial Overview: -- Revenue reduced by 26% to US$20.5 million (H1 2022 restated*: US$27.6 million) -- Gross profit margin of 40.9% (H1 2022 restated*: 41.5% in H1 2022) -- Adjusted EBITDA of US-$3.6 million (H1 2022 restated*: US$0.7 million) -- Operating loss of US-$6.0 million (H1 2022 restated*: US-$1.6 million) -- Loss after taxation of US$-6.5 million (H1 2022 restated*: profit of US-$1.9 million) -- Cash balance as at 30 June 2023 of US$7.3 million * Details on restatements of prior year financial information are disclosed in Note 2 of t he Consolidated Financial Statements. Operational Overview: Trading conditions for the markets of our commercialized product range continued to be challenging during H1 2023 and, as highlighted in detail in our Full Year results for the 12 months to 31 December 2022, the Company took decisive steps to reduce its cost base and reorganize the business to maintain its innovation and differentiation capabilities during the period under review. With costs reduced and operations adapted in light of the challenging headwinds our entire industry is facing, the Company expects H2 2023 trading to stabilize ... Liquidity as of 30 June 2023 & Going Concern Assessment As of June 30, 2023, the Company reports a cash balance of US$7.3 million (December 31, 2022: US$8.5 million). To manage its cash balance, the Group has access to credit facilities totalling CHF9.0 million (approximately US$9.8 million as of September 30, 2023). The credit facilities are in place with two different banks and both contracts have materially the same conditions. The facilities are not limited in time, can be terminated by either party at any time and allow overdrafts and fixed cash advances with a duration of up to twelve months. As of September 30, 2023, the Group has drawn CHF6.3 million of the facilities (CHF2.4 million as of December 31, 2022) (see Note 2 for details including maturity dates). The facilities are not committed, but the Board has not received any indication from financing partners that facilities are at risk of being terminated. Furthermore, the Board is in discussions with financial institutions to replace the currently uncommitted credit facilities by committed, long-term facilities, but the outcome of these discussions remains uncertain. The Group's directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future and operate within its credit facilities for the period 12 months from date of signature. Nevertheless, the Board acknowledges the uncommitted status of the facilities which could be terminated requiring the refinancing of debts, and which casts material uncertainty on the going concern assessment until appropriate longer-term funding is in place. Further disclosures on the going concern assessment are made in the notes to the financial statements. ..." So HEIQ expects H2 trading to "stabilize". I take that to mean that they expect it to be similar to H1, as opposed to getting worse. Though this is still just an expectation, two thirds of the way through this period. And this is despite having reduced costs in H1. Other things being equal, such stabilisation would suggest a H1 operating loss of c. US$6M., like H1. Cash at 30.6.23 was US$7.3M., but this is balanced out by the short-term borrowings of US$7.47M. at 30.6.23. HEIQ has CHF9.0 million (equating to c. US$9.8 million as at 30.9.23) of (discretionary) credit facilities, but as at 30.9.23 had drawn down 70% of these, with just CHF2.7 million left, having drawn down CHF3.9 million in the first 9 months of this year, an average drawdown rate of CHF1.3 million per quarter. So at this rate of drawdown the facility would be exhausted by early April 2024. That seems incongruous with the company's indication that funds should last until late October next year. In order to last that long, with no additional injection of funds, you would think that trading would have to improve significantly ... whereas the company is only expecting stabilisation. Replacement of the short-term credit facility with a long-term facility of the same size wouldn't actually provide more money. So the bottom line is that the company looks to be running out of money, and has a bad track record of misleading investors with its forecasts. A big placing looks to be the most likely outcome, probably within the next few/several months. And in the current very bad fundraising environment for loss-making companies like this, that is likely to be at a lot less than the current share price of 20p. That I believe is why HEIQ's CEO hasn't bought shares since the company's return from suspension, despite coming out of the close period: he's 'keeping his powder dry' for a forthcoming discounted placing. And if he apparently doesn't have confidence in the current s.p., despite the big drop since his buys in January at 28p average & 34p, then why should anyone else? |
Posted at 03/11/2023 11:24 by catabrit Interesting RNS. I am surprised that Carlo did not buy. No disrespect to Darren who I am sure is a good investor but the fact that Amati sold almost their entire stake at the bottom says everything you need to know about HEIQ’s future shareholder base I.e it ain’t going to be institutional. The rise in the share price has made me look very stupid (happens all the time in the short term so I get used to it!) but I stand behind my thesis. I think this will be in the doldrums for a long time. Even the moonshot bets are way off from meaningful revenue and with rates at 5% and a tonne of VC type bets available at 15-35p in the £ (GROW and multiple others), I can’t see why the market would value HEIQ’s portfolio at a premium. It would not surprise me if this slowly faded down. It is now at a market cap where the vast majority of money just doesn’t give a damn. I look at the balance sheet and the cash flow statement and I look at the markets that HEIQ operates in and there is nothing that entices me to buy it. I suppose people will fall in and out of love with the story and good luck to them. |
Posted at 01/11/2023 19:22 by hedgehog 100 Packman,It's over a year since HEIQ filed this complaint:- 10/10/2022 06:00 UK Regulatory (RNS & others) HeiQ PLC Files Breach of Exclusive Agreement Complaint LSE:HEIQ Heiq Plc Though as far as I'm aware, they still haven't commenced legal proceedings. We don't have the detail to give an informed opinion on the merits of this claim, so here are just a few general points of mine, for what they're worth:- • Things are moving very slowly, and will probably continue to do so. • There are two sides to every story. • The market will likely largely discount any potential settlement until any is achieved. • This claim is probably as likely to put off potential investors as attract them. |
Posted at 30/10/2023 13:16 by hedgehog 100 30/10/2023 07:00 UK Regulatory (RNS & others) HeiQ PLC Results for year ended 31 December 2022 LSE:HEIQ Heiq Plc" ... Financial Overview: -- Revenue reduced 14.8% to US$47.2 million (FY 2021 restated: US$55.4 million*) -- Gross profit margin down 17.3% to 28.5% (FY 2021 restated: 45.8%*) -- Adjusted EBITDA decreased to US-$12.2 million (FY 2021 restated: US$4.5 million*) -- Operating loss of US-$29.2 million (FY 2021 restated: US$-1.4 million*) -- Loss after taxation of US$-29.8 million (FY 2021 restated: US$-1.4 million*) -- Cash at year-end of $8.5m with net debt (including lease liabilities) of US$3.7 million ..." 30/10/2023 07:01 UK Regulatory (RNS & others) HeiQ PLC Interim Results LSE:HEIQ Heiq Plc "Half year results for the period ended 30 June 2023 HeiQ Plc (LSE:HEIQ), a leading company in materials innovation and hygiene technologies, announces its interim results for the period ending 30 June 2023 ("H1 2023"). These results are published concurrently with the Company's final results for the full year ended 31 December 2022 ("FY 22"). Restoration of Trading: As detailed in the FY 22 results, upon uploading the Annual Report 2022 to the National Storage Mechanism, expected to be completed today, the Company will make an immediate request to the FCA for the Company's Ordinary Shares to be restored to trading on the Main Market of the London Stock Exchange as soon as practicable thereafter. A further announcement will be made confirming the exact time and date of resumption of trading. Financial Overview: -- Revenue reduced by 26% to US$20.5 million (H1 2022 restated*: US$27.6 million) -- Gross profit margin of 40.9% (H1 2022 restated*: 41.5% in H1 2022) -- Adjusted EBITDA of US-$3.6 million (H1 2022 restated*: US$0.7 million) -- Operating loss of US-$6.0 million (H1 2022 restated*: US-$1.6 million) -- Loss after taxation of US$-6.5 million (H1 2022 restated*: profit of US-$1.9 million) -- Cash balance as at 30 June 2023 of US$7.3 million Operational Overview: Trading conditions for the markets of our commercialized product range continued to be challenging during H1 2023 and, as highlighted in detail in our Full Year results for the 12 months to 31 December 2022, the Company took decisive steps to reduce its cost base and reorganize the business to maintain its innovation and differentiation capabilities during the period under review. With costs reduced and operations adapted in light of the challenging headwinds our entire industry is facing, the Company expects H2 2023 trading to stabilize. Post Period: The Company is closely monitoring the market and is ready to take further cost reduction action, should it need to. We continue to add value to our high potential key innovation initiatives through focused investment, to position ourselves for when the macro-economic difficulties abate. While the Board considers the Company has adequate resources, it is in discussions with financial institutions to replace the currently uncommitted credit facilities by committed, long-term facilities. Equity analyst and shareholder presentations: Following the resumption of trading in its ordinary shares the Company will announce registration details for two live presentations. These presentations will cover today's results and will be held separately for both equity analysts and investors. ..." |
Posted at 27/10/2023 17:01 by pugugly Market now closed - No announcement yet 7 hours left!!!!!!"23 October 2023 HeiQ Plc ("HeiQ" or "the Company") Notice of Results and Audit Update HeiQ (LSE:HEIQ), a leading company in materials innovation and hygiene technologies, announces that its audited accounts for the year ended 31 December 2022 ("2022 Accounts") will be published this week alongside its results for the six months ended 30 June 2023 ("H1 2023"). |
Posted at 26/10/2023 16:19 by hedgehog 100 "RENEW, RE:NEWCELL, (SE0014960431)""Company Profile Re:NewCell AB is a fast-growing Swedish textile recycling company with world-class technology and a team of people on a mission to change the textile industry. Its product is called Circulose, and It makes out of 100% textile waste. Renewcell’s patent-protected recycling technology breaks down used cotton and other cellulose-rich textiles and transforms them into a new, biodegradable raw material: Circulose pulp, and Brands use it to replace high-impact raw materials like fossil oil and cotton in textile products." Thanks for flagging up RENEW, Catabrit. RENEW floated on the Nasdaq First North (in Stockholm) on 26th. November 2020, just eleven days before HEIQ floated on the London Stock Exchange's Main Market. And their share price charts since then are quite similar. RENEW quickly rose from about eleven Euros to about thirty Euros, before falling all the way back to below one Euro: currently 0.67 Euros, market cap. c. £28M. Euros. That's a decline from its high of about 97.75%. HEIQ also rapidly more than doubled from its float price, before entering the same sort of multi-year decline. And a decline of the same percentage from its high, a high of c. 240p in HEIQ's case, would take HEIQ to c. 5.4p. |
Posted at 26/10/2021 09:35 by bad gateway Missed the press conference. Decent piece on the website though and sounds quite a product for our new net zero world.CALL FOR EARLY ADOPTERS OF CELLULOSIC CLIMATE POSITIVE HEIQ AEONIQ YARN October 26, 2021 HeiQ announces a potential game-changer for the textile industry with the introduction of HeiQ AeoniQ – a high performance cellulose yarn based on a new fiber derived from carbon negative materials. This new fiber, which is derived from third generation cellulosic biopolymers, is advancing to pilot production prior to mass commercialization. The LYCRA Company is first to join HeiQ as a development partner. Whether it is cotton, wool or synthetic polymers, global textile production has a significant environmental impact with the industry responsible for more than 10% of global greenhouse gas emissions and over 20% of wastewater worldwide1. Conventional cellulosic fiber production uses arable land during growth and has limited design versatility, while raw materials for fossil-based synthetic materials are finite. Existing methods to recycle textile fabrics and garments made with all fibers are, for the most part, still not at scale and most fibers – whether synthetic or natural – take many years to degrade in landfills or oceans, leading to environmental build up. HeiQ AeoniQ cellulosic yarn made of climate positive raw materials HeiQ AeoniQ yarns (Aeon: striving for eternal circularity) are made out of cellulosic biopolymers that during growth bind carbon from the atmosphere while generating oxygen. This high-performance yarn is positioned to potentially substitute synthetic filament yarns which constitute over 60% of global annual textile output of 108 million metric tons 2. Further, when compared to conventional cellulosic products, HeiQ AeoniQ yarns do not draw on arable land, pesticides or fertilizer in their production. HeiQ AeoniQ yarns are designed for cradle-to-cradle circularity and can be recycled repeatedly while maintaining consistent fiber quality. The manufacturing process is expected to consume 99% less water than cotton yarns and HeiQ AeoniQ is designed to offer comparable performance properties to polyester, nylon and conventional regenerated cellulose yarns. Inviting first adopters HeiQ’s leading industry experts stand ready to deliver the first HeiQ AeoniQ yarns from the pilot production plant in Q2 2022. Given the outstanding qualities, the unique decarbonizing potential offered and outstanding ESG3 credentials, HeiQ is inviting a maximum of 20 sustainability-drive The LYCRA Company as a primary development partner HeiQ announces that The LYCRA Company, with its renowned collection of brands, global retail customer network and fabric innovation capabilities, will be a primary apparel development partner for HeiQ AeoniQ yarns with an exclusivity for stretch and performance fabrics. The LYCRA Company has a complete range of certified, sustainable products and is continuously complementing this range via the development of new types of LYCRA® fiber. These fibers have the potential to be combined with HeiQ AeoniQ yarn to create unique decarbonizing and degradable elastic fabrics. HeiQ Group Co-founder and CEO, Carlo Centonze states:“Climat The LYCRA Company CEO Julien Born notes: “With our future company strategy centering on sustainable solutions for the textile industry, we are proud to partner with HeiQ in both the technical development and commercialization of this fiber. The industry is ready for innovations such as HeiQ AeoniQ, and by combining our capabilities with those of HeiQ, we are truly well positioned to learn quickly and maximize the huge potential of this new technology.” Mr. Martin Gebert-Germ, a viscose filament yarn expert with 30 years of experience in the textile industry, stated, “This technology is the game changer for the whole textile industry.” Mr. Gebert-Germ, will join the newly-established HeiQ GmbH Austria as CEO and will be leading the HeiQ AeoniQ business from November 2021. The World Bank 2019 Statista Environment, Social, Governance |
Posted at 03/3/2021 07:10 by jammytass 3 March 2021HeiQ Plc ( Acquisition of 51% of Industrial Biotech Business, Chrisal HeiQ Plc (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce that it has signed an agreement to acquire 51% of the share capital and voting rights of Chrisal N.V., Belgium ("Chrisal", "the Acquisition"). The Acquisition is for a consideration of €7.5 million, with €5.0 million payable in cash and €2.5 million through the issue of 1,101,928 new ordinary shares by HeiQ. On completion, Chrisal will be renamed HeiQ Chrisal. Chrisal is a profitable industrial biotechnology company and a leader in innovative ingredients and consumer products that incorporate the benefits of probiotics and synbiotics. It has 120 products within its three technology platforms that create healthy and sustainable microbial ecosystems. The application of its proprietary technology includes cosmetics, personal care, textiles, wound dressings, water purification, air treatment and cleaning products. Chrisal has recently developed a synbiotic interior cleaner, Synbio®, for healthcare and hospitals, a project sponsored by The Gates Foundation. Early results have indicated Synbio® cleaners to be equal to disinfectants and detergents but without bacterial resistance downsides, while offering enhanced cleaning performance. The Acquisition is aligned with HeiQ's strategy of becoming a global leader in materials innovation. It also solidifies HeiQ's position as a profitable and fast-growing pioneer in the $24 billion global textile chemicals market. HeiQ already directly serves the $10 billion antimicrobial textile market with its HeiQ Viroblock and HeiQ Pure technology platforms and the Acquisition will strengthen its presence with a complementary probiotic platform while enabling it to enter the new adjacent and lucrative markets of surface hygiene treatment, water purification and probiotic personal care. Additional Highlights · Chrisal recorded revenue of €5.5 million for the 12 months to 31 December 2020, an increase of 62% compared to 2019, and an operating profit of €1.6 million (28.9%) - unaudited. · Chrisal has over 500 commercial customers in 25 countries, including hospitals, food and cosmetic manufacturers, presenting HeiQ with compelling cross-selling opportunities for its existing core product range. Chrisal will benefit from HeiQ's extensive customer and distribution network, as well as its marketing prowess. · Chrisal customers include Q viva, Ahava, Atena-Alfa, Probilife, Sonax, Woellner and Greenspeed · The Acquisition includes a bottling facility in Belgium. This is an important infrastructure requirement for HeiQ's ambitions in functional textile aftercare and other fields. · The current Chrisal President and Founder Corrie Gielen and its CEO/CTO Dr. Robin Temmerman will continue to lead the business, supported by the existing Chrisal team. · HeiQ co-Founder and Group CEO Carlo Centonze as well as Group CFO Xaver Hangartner will join the HeiQ Chrisal Board of Directors and will explore further synergies over the course of 2021. · HeiQ Chrisal will be responsible for the creation, production and commercialisation of its products, with HeiQ acting as its corporate service hub and extended commercialization arm. · Chrisal's patented technology carries the prestigious EU Ecolabel, a label of excellence that is awarded solely to products meeting high environmental standards throughout their lifecycle. HeiQ co-founder and CEO Carlo Centonze said: "The acquisition of a majority stake in Chrisal brings multiple benefits to HeiQ and its shareholders. HeiQ Chrisal will provide us with revenue from other fast-growth markets adjacent to those we serve already, as well as exciting cross-selling opportunities for our and their existing core product range. The acquisition will progress our direct to consumer offer and enlarges our product offering to hygiene-sensitive environments, such as the healthcare sector. "Chrisal's technology platform includes an anti-allergen effect for mattresses and bedding, microbial and viral protection for surfaces, anti-inflammatory effects in wound dressings, probiotic skin enhancing cosmetics, algae and biofilm control in drinking water as well as advanced synbiotic protection to replace the resistance-creating antibiotics in animal husbandry. We are particularly excited about Chrisal's synbiotic technology solution for healthcare and hospitals for which full clinical results are due to be published imminently in a leading journal. "HeiQ is increasingly becoming more than a textile technology company; we are innovating materials more broadly. This acquisition of a leading probiotics business is aimed at making HeiQ a leader in probiotic innovation, positioning us well to serve many lucrative segments of this fast growth USD 50 billion market. "Chrisal's culture of entrepreneurship, people empowerment, sustainability, innovation and lean processes are a perfect match with HeiQ. I expect this partnership to become a great success and we will look forward to working closely with Corrie, Robin and the rest of the Chrisal team." Corrie Gielen, President of Chrisal commented: "For 30 years Chrisal has built on new technologies to improve our world in a sustainable way. With our latest patented Synbio® technology we have found the best solution to strengthen products, people and our environment. We are confident that the new partnership with HeiQ will bring us the additional competences and network needed to globalize this beautiful and groundbreaking technology. Together we combine the best of nature with the latest in science to make the difference for a better world." Further Information on Chrisal: Chrisal is an industrial biotechnology leader in prebiotic, probiotic and synbiotic technologies and products. With its 120 products, Chrisal serves commercial and consumer customers operating in the markets of cosmetics, personal care, textiles, wound dressings, water and air purification and cleaning solutions for hospitals and animal husbandry. Early results from clinical trials for Chrisal's patented Synbio®, an active synbiotic surface cleaner, suggest that it could be the next generation technology to probiotic surface cleaners, such as Reckitt Benckiser's VEO. Chrisal technology carries the prestigious EU Ecolabel, a label of environmental excellence that is awarded solely to products meeting high environmental standards throughout their lifecycle. The industrial biotech acquisition will provide HeiQ access to the technology platform of prebiotics, probiotics and postbiotics for bio-based odor & stain control for carpet & footwear, anti-allergen effect in mattress and bedding, microbial and viral protection for surfaces, anti-inflammatory effect in wound dressings, probiotic skin enhancing cosmetics, algae and biofilm control in drinking water as well as advanced synbiotic protection replacing the resistance-creating antibiotics in animal husbandry. With this strategic acquisition HeiQ enters the broader market of surface management and accesses a bio-based green complementary technology platform to its antimicrobials. Chrisal's 120 products strengthen HeiQ's global product offering and will facilitate HeiQ's existing technology platforms into new markets. Chrisal has a large, efficient manufacturing footprint in Lommel, Belgium and brings into the HeiQ group the strategic capability of bottling, a step required for HeiQ's B2C products ambitions in functional textile aftercare and other fields. Chrisal also includes a microbiology and molecular diagnostics lab for R&D and QC activities. HeiQ Chrisal, the new corporate name for Chrisal, will continue to be led by President and Founder Corrie Gielen, its CEO/CTO Dr. Robin Temmerman as well as the entire Chrisal team. The entrepreneurial drive will be strengthened by HeiQ's Group support functions in Rapid & Deep R&D, Branding & Marketing, Regulatory and Compliance as well as Commercialisation. HeiQ co-Founder and Group CEO Carlo Centonze as well as Group CFO Xaver Hangartner will join the HeiQ Chrisal Board of Directors. HeiQ Chrisal will be responsible for the creation, production and commercialization of its products, with the HeiQ Group acting as its corporate service hub and extended commercialization arm. Together, the newly enlarged Board will explore further synergies over the course of 2021. Issue of Equity and Total Voting Rights The Company will issue 1,101,928 new ordinary shares ("Consideration Shares") to the sellers of Chrisal, at a price of 1.9596p per share, which is the average 5 day closing price prior to signing, in order to part satisfy the consideration due. Applications will be made for the Consideration Shares to be admitted to the standard segment of the Official List, and to trading on the London Stock Exchange's Main Market ("Admission"). It is expected that Admission will become effective, and that dealings in the new Ordinary Shares are expected to commence, at 8.00 a.m. on 9 March 2021. Following Admission, the total number of Ordinary Shares in issue will be 126'993'832 and the total number of voting rights will therefore be 126'993'832. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules. This announcement contains inside information. For further information, please contact: HeiQ Plc |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
